X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/biocity-announces-fda-clearance-of-the-investigational-new-drug-application-for-its-first-in-class-antibody-drug-conjugate-targeting-glypican-3-302111894.html
https://www.prnewswire.com/news-releases/biocity-announces-enrollment-completion-of-the-iga-nephropathy-igan-cohort-in-the-randomized-placebo-controlled-phase-ii-clinical-trial-of-the-eta-receptor-antagonist-sc0062-302071156.html
https://www.prnewswire.com/news-releases/biocity-announces-the-first-patient-dosed-with-its-anti-tim-3-mab-bc3402-in-combination-with-imfinzi-for-the-treatment-of-advanced-hepatocellular-carcinoma-in-a-phase-ibii-trial-302020549.html
https://www.prnewswire.com/news-releases/biocity-signs-collaboration-agreement-with-astrazeneca-on-bc3402-a-monoclonal-antibody-targeting-anti-tim-3-in-combination-with-imfinzi-durvalumab-for-the-treatment-of-advanced-hepatocellular-carcinoma-in-china-301941128.html
https://www.prnewswire.com/news-releases/biocity-announces-fda-clearance-of-investigational-new-drug-application-for-its-first-in-class-cd3egfr-bispecific-antibody-301894395.html
https://www.prnewswire.com/news-releases/biocity-announces-the-first-patient-dosed-with-its-first-in-class-cdh3-targeting-adc-bc3195-in-a-phase-1-trial-301881671.html
https://www.prnewswire.com/news-releases/biocity-announces-initiation-of-a-phase-2-trial-for-sc0062-a-promising-eta-receptor-antagonist-for-chronic-kidney-disease-301857468.html
Market Place
Share 
